Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028
As
per Triton’s analysis, Latin America’s immunoglobulin market is likely to
develop with a CAGR of 5.29% over the forecasting years 2022-2028.
Report scope can be customized per your requirements. Request For Customization
The
countries analyzed in this region include:
• Mexico
• Brazil
• Rest of Latin America
The
immunoglobulin market in Latin America is expected to bolster due to the
presence of market leaders, such as Pfizer. Moreover, the region focuses on
bringing innovation through product developments and launches along with
significant investments and growth in biotechnology and pharmaceuticals.
Besides, the support from the government in product approvals has also
contributed to the growth of the studied market.
Brazil
witnessed a boost in the immunoglobulin market because of strategic initiatives
by the top players in developing products. In addition to this, the increase in
product approvals by the government is likely to have a positive impact on the
overall market’s growth. For instance, The Brazilian Health Regulatory Agency
has approved Celltrion Healthcare’s regdanvimab for emergency use. It is a
monoclonal antibody treatment for patients with mild-to-moderate COVID-19.
Additionally,
in 2019, SK Plasma won a bid of $20 million to supply LIV-Gamma to Brazil’s
Ministry of Health. It helps reduce the risk of infection in patients with poor
immune systems and those suffering from chronic lymphocytic leukemia, bone
marrow transplantation, etc. Such developments in the country’s biotech and
pharma industry are augmenting the market’s growth process.
On
the other hand, Argentina showcased significant developments in the
immunoglobulin market, which is anticipated to open new avenues. For instance,
Scientists at the Leloir Institute Foundation and CONICET launched a new
serological test for COVID-19 called COVIDAR IgM. It helps detect IgM
immunoglobulin, the first antibody produced by the immune system to fight
infection. Likewise, in 2020, mAbxience set up a new biosimilar monoclonal
antibody plant in the country, and these drugs are used in treating oncological
and autoimmune diseases such as rheumatoid arthritis. Thus, all these factors
are fostering the growth of the immunoglobulin market in the country.
Intramuscular
immunoglobulin is commonly used for hyperimmune globulins such as rabies immune
globulin. Here, the intramuscular immune globulin aids in the short-term
prevention of specific infectious diseases such as hepatitis A through a single
dose. It also offers a combined or independent therapeutic treatment option for
recalcitrant suppurative skin diseases such as hidradenitis, decalvans,
suppurativa, or chronic recurrent furunculosis.
The
studied report evaluates the market’s growth based on the delivery mode,
application, end-user, sales channel, and type. Here,
the delivery mode segment contains intravenous, intramuscular, and
subcutaneous.
The
leading players considered in the immunoglobulin market include ADMA Biologics,
Bio Products Laboratory, China Biologic Products Inc, Pfizer Inc, Kedrion
Biopharma, Takeda Pharmaceutical Company Limited, Grifols SA, and Shanghai RAAS
Blood Products Co Ltd.
Bio
Products Laboratory is a company involved in the manufacturing of human blood
plasma products. The company has plasma collection centers and is dedicated to
producing various medicines to treat immune deficiencies, bleeding disorders,
infectious diseases, and critical care. Moreover, it operates under two
divisions, BPL Therapeutics and BPL Plasma. In 2021, the company invested $31
million in a new Sterile Filing Suite, a 1,000 square meter state-of-the-art
suite that aims at supporting plasma-derived medicinal products. Besides, the
company has its presence in over 50 countries globally and was founded in 1954.
Key deliverables of the report:
· Detailed data highlighting key insights, industry components, and market strategies
· Comprehensive information and estimation of the immunoglobulin market revenue growth in Latin America and its influence on the parent market
· In-depth study of forthcoming trends in consumer behavioral patterns
· A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model
· A wide-ranging study of factors that will challenge the Latin America immunoglobulin market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize this
report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. LATIN
AMERICA IMMUNOGLOBULIN MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY
INSIGHTS
2.2.1. DEVELOPMENT
OF NEW PURIFICATION METHODS
2.2.2. INCREASING
PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6.2. PARTNERSHIPS
& AGREEMENTS
2.7. MARKET
DRIVERS
2.7.1. GROWTH
IN THE GERIATRIC POPULATION
2.7.2. PREVALENCE
OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3. INCREASING
RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET
CHALLENGES
2.8.1. HIGH
COST OF THERAPY
2.8.2. HIGH
RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2. GROWING
CLINICAL TRIALS
3. LATIN
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4. LATIN
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5. LATIN
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA
GLOBULINEMIA
5.2. CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY
IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA
GRAVIS
5.5. MULTIFOCAL
MOTOR NEUROPATHY
5.6. IDIOPATHIC
THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY
MYOPATHIES
5.8. SPECIFIC
ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE
SYNDROME
5.10. OTHER
APPLICATIONS
6. LATIN
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS
& CLINICS
6.2. HOMECARE
7. LATIN
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL
PHARMACY
7.2. SPECIALTY
PHARMACY
7.3. OTHER
SALES CHANNELS
8. LATIN
AMERICA IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK
8.1. BRAZIL
8.2. MEXICO
8.3. REST
OF LATIN AMERICA
9. COMPETITIVE
LANDSCAPE
9.1. BIOTEST
AG
9.2. CHINA
BIOLOGIC PRODUCTS INC
9.3. GRIFOLS
SA
9.4. LFB
GROUP
9.5. CSL
BEHRING
9.6. KEDRION
BIOPHARMA
9.7. OCTAPHARMA
AG
9.8. TAKEDA
PHARMACEUTICAL COMPANY LIMITED
9.9. BIO
PRODUCTS LABORATORY
9.10. SHANGHAI
RAAS BLOOD PRODUCTS CO LTD
9.11. PFIZER
INC
9.12. SANQUIN
PLASMA PRODUCTS BV
9.13. ADMA
BIOLOGICS
9.14. SICHUAN
YUANDA SHUYANG PHARMACEUTICAL CO LTD
9.15. KAMADA
LTD
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)
FIGURE 14: LATIN AMERICA IMMUNOGLOBULIN
MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $
MILLION)
FIGURE 15: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $
MILLION)
FIGURE 16: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 18: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028
(IN $ MILLION)
FIGURE 19: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)
FIGURE 20: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $
MILLION)
FIGURE 21: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)
FIGURE 22: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 25: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: LATIN AMERICA
IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: BRAZIL
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: MEXICO
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: REST OF LATIN
AMERICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)